Serum 5-Hydroxyindoleacetic Acid Measurements for the Diagnosis and Follow-up of Carcinoid Syndrome
The Journal of Clinical Endocrinology & Metabolism · 18.11.2025 · 110 (12) · e3980-e3988
DOI: 10.1210/clinem/dgaf263 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 02.05.2025. Verfasst von Makarious Kerolles und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Section of Endocrinology, ENETS Center of Excellence, Erasmus Medical Center Cancer Institute, 3015 GD Rotterdam, Th…. Hauptthemen laut MEDLINE: Hydroxyindoleacetic Acid, Malignant Carcinoid Syndrome. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Context
The biochemical diagnosis of carcinoid syndrome (CS) is established through the measurement of 24-hour urine 5-hydroxyindoleacetic acid (5-HIAA), but these measurements are prone to sampling error and may be troublesome for patients. Serum 5-HIAA measurements might constitute a more reliable and convenient alternative to diagnose CS.
Objective
To assess the diagnostic value of serum 5-HIAA measurements in patients with CS.
Design
Retrospective cohort study.
Setting
Tertiary care hospital. Patients 379 patients with a neuroendocrine tumor (NET), of whom 136 (35.9%) had CS; 153 control samples were included.
Intervention
Paired serum and 24-hour urine 5-HIAA measurements. Main Outcome Measure(s) Performance of serum and 24-hour urine 5-HIAA for the diagnosis of CS, measured by area under the receiver operating characteristic curve (AUROC).
Results
Serum 5-HIAA performance was similar to that of 24-hour urine 5-HIAA for the diagnosis of CS in the total NET cohort (n = 379, AUROC 0.824 vs 0.843, P = .50) and in a subgroup of somatostatin analog (SSA)-naïve patients (n = 141, AUROC 0.915 vs 0.938, P = .66). Optimal cutoff value of serum 5-HIAA for the diagnosis of CS was 139.4 nmol/L (sensitivity 96.3%, specificity 87.6%) as determined in a subgroup analysis of SSA-naive patients with CS and controls. Serum 5-HIAA correlated well with 24-hour urine 5-HIAA (r = 0.892, P < .001) and the presence of flushing, diarrhea, and carcinoid heart disease (odds ratio 1.047-1.073 for every 100 nmol/L increase, P < .001).
Conclusion
Serum 5-HIAA measurements are equivalent to 24-hour urine 5-HIAA measurements for the diagnosis of CS in patients with NET and form an accessible alternative.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Section of Endocrinology, ENETS Center of Excellence, Erasmus Medical Center Cancer Institute, 3015 GD Rotterdam, The Netherlands.
- Department of Clinical Chemistry, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands.
- Department of Endocrinology, Diabetes and Metabolism, New York University Langone Medical Center, New York, NY 10017, USA.
ORCID-Profile: Makarious Kerolles, Merijn C F Mulders, Mina Mirzaian, Sjoerd A A van den Berg, Richard A Feelders, Wouter W de Herder, Johannes Hofland
Zitieren
APA
Kerolles, M., Mulders, M. C. F., Mirzaian, M., van den Berg, S. A. A., Feelders, R. A., de Herder, W. W., & Hofland, J. (2025). Serum 5-Hydroxyindoleacetic Acid Measurements for the Diagnosis and Follow-up of Carcinoid Syndrome. The Journal of Clinical Endocrinology & Metabolism, 110(12), e3980-e3988. https://doi.org/10.1210/clinem/dgaf263
Vancouver
Kerolles M, Mulders MCF, Mirzaian M, van den Berg SAA, Feelders RA, de Herder WW, et al. Serum 5-Hydroxyindoleacetic Acid Measurements for the Diagnosis and Follow-up of Carcinoid Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2025;110(12):e3980-e3988. doi:10.1210/clinem/dgaf263
BibTeX
@article{Kerolles2025,
author = {Kerolles, Makarious and Mulders, Merijn C F and Mirzaian, Mina and van den Berg, Sjoerd A A and Feelders, Richard A and de Herder, Wouter W and Hofland, Johannes},
title = {Serum 5-Hydroxyindoleacetic Acid Measurements for the Diagnosis and Follow-up of Carcinoid Syndrome},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {12},
pages = {e3980--e3988},
doi = {10.1210/clinem/dgaf263}
}
EUVIMED